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Introduction: The prevalence of renal fibrosis is higher in older than in younger individuals. Through paracrine
activity, bone marrow mesenchymal stem cell-derived microvesicles (BM-MSC-MVs) influence the process of renal
fibrosis. Differences in microRNA (miRNA) expression of BM-MSC-MVs that correlate with the age of the subjects
and the correlation between miRNA expression and the process of renal fibrosis have not been established. The
present study aimed to analyze differences in miRNA expression of BM-MSC-MVs between young or older rats and
its influence on tumor growth factor-beta 1 (TGF-β1)-mediated epithelial-mesenchymal transition (EMT) of HK2 cells
to explore the causes of renal fibrosis in aged tissues.
Methods: miRCURY LNA Array (version 18.0) was used to identify differentially expressed miRNAs in BM-MSC-MVs
of 3- and 24-month-old Fisher344 rats. Reverse transcription-polymerase chain reaction was used to verify miRNA
levels in BM-MSC-MVs and in the serum of rats. A TGF-β1-mediated EMT model was used to study the effects of
BM-MSC-MVs and differentially expressed miRNAs on EMT.
Results: BM-MSCs from older rats showed more severe aging phenotypes compared with those of young rats. In
addition, the growth rate and cell migration of BM-MSCs derived from older rats were significantly reduced. In
secreted BM-MSC-MVs, the expression of miR-344a, miR-133b-3p, miR-294, miR-423-3p, and miR-872-3p was
significantly downregulated in older rats than in younger rats (P < 0.05), and the serum level of these miRNAs
exhibited the same patterns. Intervention using BM-MSC-MVs resulted in the weakening of TGF-β1-mediated EMT in
the aged rats. MiR-344a, miR-133b-3p, and miR-294 affected TGF-β1-mediated EMT in HK2 cells. Among these,
miR-133b-3p and miR-294 significantly inhibited TGF-β1-mediated EMT in HK2 cells (P < 0.05).
Conclusions: In older rats, the inhibitory effect of BM-MSC-MVs on TGF-β1-mediated HK2 cell EMT was weaker than
that observed in younger rats. In addition, miR-133b-3p and miR-294, which were downregulated in BM-MSC-MVs
of older rats, remarkably inhibited TGF-β1-mediated EMT in HK2 cells, suggesting that these may play a role in the
fibrosis of aging renal tissues.* Correspondence: xfssun@126.com; zhaoweihong_1@medmail.com.cn
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Chronic kidney disease (CKD) affects older people at a
higher rate compared with younger subjects. According
to systematic reviews and analyses, the incidence of
CKD has significantly increased with the improvement
on the life span of the general population [1]. Based on
Chinese epidemiological surveys on CKD, the average
age of patients with stage 3 CKD or higher is 63.6 years
old. With an increase of 10 years in age, the risk of epider-
mal growth factor receptor (eGFR) is less than 60 ml/min
per 1.73 m2, which represents the renal glomerular filtra-
tion rate, increasing by 1.74-fold [2]. According to the US
National Health and Nutrition Examination Survey, the
incidences of phase 1 or 2 CKD were 2 %–3 % among
people within the age of 20 to 39 years and 9 %–10 %
among people above 70 years old, whereas those of phase
3 or 4 CKD were 0.2 %–0.7 % among people with the age
range of 20 to 39 years old and 27.8 %–37.8 % among
people above 70 years old [3]. Tubulointerstitial fibrosis
plays an important role in the course of CKD and is a typ-
ical characteristic of aged kidney tissues [2, 3]. Tumor
growth factor-beta 1 (TGF-β1) is an important growth fac-
tor that induces epithelial-to-mesenchymal transition
(EMT) and promotes tubulointerstitial fibrosis [4].
Bone marrow mesenchymal stem cells (BM-MSCs) are
a pluripotent cell population that can differentiate into
various cell types such as fat, bone, muscle, and skin
cells as well as show significant therapeutic effects
against many diseases [5–7]. It has been recently found
that BM-MSCs change accordingly with the age of an in-
dividual [8–10]. With aging, BM-MSCs decrease in
number [11, 12], and the functional factors they secrete
may also change [12–14]. Microvesicles (MVs) are
small-particle exosomes that are secreted by BM-MSCs
and contain a number of bioactive substances such as
proteins, lipids, mRNA, and microRNA (miRNA). These
also have good therapeutic effects against acute and
chronic diseases [15–17]. miRNAs are important genetic
regulatory factors of BM-MSC-MVs that identify target
mRNAs through base pairing. Moreover, based on the
degree of complementarity, miRNAs can guide silencing
complexes to degrade target mRNAs or downregulate
the expression of mRNAs. Previous studies have shown
that miRNAs are closely linked to the occurrence of dis-
eases and the aging process [18–20]. However, informa-
tion on differences in miRNA expression in BM-MSC-
MVs between young and elder individuals and whether
these differences can further promote renal fibrosis and
aging of kidney is unknown. The present study aimed to
analyze differences in miRNA expression of BM-MSC-
MVs between young or elder rats as well as the effect of
differentially expressed miRNAs on TGF-β1-mediated
EMT of HK2 cells in relation to the pathogenesis of
renal fibrosis in aged tissues.Methods
Cell culture and identification of BM-MSCs
Animal welfare and experimental procedures were all
carried out in accordance with the Guide for the Care
and Use of Laboratory Animals (Ministry of Science and
Technology of China, 2006) and were approved by the
animal ethics committee of the General Hospital of the
People’s Liberation Army. BM-MSCs were extracted
from 3- and 24-month-old Fisher344 rats [16]. The iso-
lated primary BM-MSCs were cultured in complete
medium (Cyagen Bioscience Inc., Santa Clara, CA, USA).
After the cells were passaged to P2, BM-MSCs were iden-
tified by flow cytometry by using cell surface markers,
CD44, CD105, CD146, and CD45 (BioLegend Inc., San
Diego, CA, USA).
Proliferation, migration, and differentiation of BM-MSCs
BM-MSC proliferation assay
Both P2 BM-MSCs from young and elder rats were
counted after trypsinization by using 0.25 % trypsin
(Corning, Corning, NY, USA), and then approximately
10,000 cells were resuspended in 100 μl of media and
seeded onto each well of a 96-well plate. After culturing
for 4 days, each well was supplemented with 10 μl of a
cck-8 solution (Dojindo Inst. Biotech, Shanghai, China).
The plate was cultured for 3 h in an incubator. The
absorbance at a wavelength of 450 nm was measured by
using a microplate reader. Each group had five replicate
experimental sets.
BM-MSC migration assay
Polycarbonate membrane transwell inserts (8 μm) were
used (Corning). Before cell inoculation, upper transwell
chambers were equilibrated for 30 min by using serum-
free RPMI 1640 medium (Corning). Then in the un-
coated upper chambers, 1 × 105 P2 BM-MSCs, which
had been resuspended in serum-free RPMI 1640
medium, were inoculated. In the lower chambers, nor-
mal medium containing 10 % serum (Cyagen Bioscience
Inc.) was added. After incubating for 24 h, cells that had
not migrated across the polycarbonate membranes were
gently wiped off. Then the cells on the underside of the
membranes were fixed for 30 min with 4 % formalde-
hyde and stained with crystal violet (Beyotime Institute
of Biotechnology, Jiangsu, China). Cells that migrated
across the polycarbonate membrane were imaged and
counted by using an inverted microscope.
BM-MSC osteogenic differentiation assay
When the cells were 60 %–70 % confluent, the complete
medium was replaced with osteogenic and induction
medium (Cyagen Bioscience Inc.). After incubation for
3–4 weeks, bone nodules were stained with Alizarin
Red S.
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When the cells were 70 %–80 % confluent, the complete
medium was replaced with an adipogenic induction
medium (Cyagen Bioscience Inc.). After incubation for 2
weeks, lipid droplets were stained by using Oil Red O.
Extraction and identification of MVs
Cells were starved overnight in serum-free medium
supplemented with 0.5 % bovine serum albumin
(Sigma-Aldrich, St. Louis, MO, USA) prior to collection
of MVs. Cell debris was removed from the supernatant
after centrifugation at 2000 × g for 20 min. The super-
natant was collected and centrifuged at 100,000 × g at 4
°C for 1 h by using a high-speed refrigerated centrifuge
(CP100WX; Hitachi, Tokyo, Japan). The pellet was re-
suspended in serum-free RPMI 1640 medium, which
was again centrifuged at 100,000 × g at 4 °C for 1 h. The
final pellet was considered to consist of MVs [17]. The
collected MVs were treated with phosphate-buffered sa-
line (PBS) and fluorescein isothiocyanate (FITC) or
phycoerythrin (PE)/CY7-labeled anti-CD44, CD29, and
alpha 4-integrin antibodies (BioLegend Inc.). Murine
IgG labeled with FITC or PE/CY7 (BioLegend Inc.) was
used as a negative control. Flow cytometry was used to
identify cell surface markers.
SA-β-Gal staining
A senescence-associated beta-galactosidase (SA-β-Gal)
staining kit was used (Beyotime Institute of Biotechnol-
ogy). P2 BM-MSCs were seeded onto a six-well plate.
When cells reached 70 % confluency, the medium was
aspirated and the cells were washed twice with PBS. The
cells were subsequently fixed with 4 % formaldehyde for
30 min and then stained for 16 h at 37 °C with an SA-β-
Gal staining reagent. Positively stained (blue) cells were
counted by using an inverted microscope, and the posi-
tive rates between the young and elder groups were
compared.
Microarray analysis of miRNAs in BM-MSC-MVs
The technology of miRCURY LNA Array (version 18.0)
(Exiqon, Vedbaek, Denmark) was adopted. RNA was ex-
tracted and purified from BM-MSC-MVs of both young
and elder groups. With an Exiqon miRCURY Hy3/Hy5
Power Labeling Kit, miRNAs were fluorescently labeled
and then hybridized in an miRCURY LNA Array Station
(version 18.0). A GenePix 4000B microarray reader was
used to measure chip fluorescence intensity. Then the
fluorescence intensity was converted to raw numeric
data by using GenePix pro version 6.0. Triplicates were
set up for both young and elder groups. Signals with
fluorescence intensities of 30 or above were selected for
group analysis. The raw signals were normalized with
the median fluorescence intensity of each chip. With thenormalized signals, different expression levels of miR-
NAs between the young and elder groups were calcu-
lated. The statistical significance of the differences in
miRNA expression between both groups was calculated
by using the t test. miRNAs with 1.5-fold or above
expression difference and P values of less than 0.05 were
selected and defined as those showing significant
differential expression. The microarray data were depo-
sited in the National Center for Biotechnology Informa-
tion Gene Expression Omnibus (GEO) public repository
and are accessible under GEO Series accession number
GSE72198.
Verification of mRNA differential expression in
BM-MSC-MVs and sera
Blood from five 3-month-old and five 24-month-old
Fisher344 rats was collected from the orbital sinus. After
centrifugation at 3000 × g for 15 min, 100 μl of serum
was collected from the supernatant. Based on methods
earlier described, BM-MSCs were extracted and cul-
tured, and the derived MVs were collected from the 10
rats. Total RNAs in sera and MVs were extracted by
using an Exiqon miRCURY RNA Isolation Kit. The cor-
responding cDNAs were synthesized by using SYBR
PrimeScript miRNA reverse transcription-polymerase
chain reaction (RT-PCR) Kit (Takara, Tokyo, Japan).
Lastly, an ABI-Prism 7500 Sequence Detection System
(Applied Biosystems, Waltham, MA, USA) and SYBR
PrimeScript miRNA RT-PCR Kit (Takara) were used to
detect the expression level of specific miRNAs (miR-
344a, miR-294, miR-872-3p, miR-133b-3p, and miR-423-
3p) and the loading control, miR-191.
TGF-β1 stimulation and miRNA transfection
HK2 cells (American Type Culture Collection, Manas-
sas, VA, USA) were cultured in 10 % fetal bovine serum
(FBS) Dulbecco’s modified Eagle’s medium/F12 (DMEM/
F12) medium (Corning). When the cells reached 50 %
confluency, serum-free DMEM/F12 medium was used
to synchronize the cells for 18 h. The HK2 cells were in-
cubated with recombinant human TGF-β1 (PeproTech
Inc., Rocky Hill, NJ, USA) at a concentration of 8 ng/ml
for 48 h to induce fibrosis with young MV (105 young
MSCs released overnight) or old MV (105 old MSCs re-
leased overnight) treatment. For the miRNA transfection
groups, miR-344a, miR-294, miR-872-3p, miR-133b-3p,
and miRNA mimic control (GeneCopoeia Inc., Rockville,
MD, USA) were transfected into the synchronized HK2
cells in accordance with the instructions of the jet-
PRIME® transfection reagent (Polyplus Transfection Inc.,
USA). Approximately 24 h after transfection, the medium
was replaced with 10 % FBS DMEM/F12 medium (Corn-
ing, Shanghai, China) containing 8 ng/ml of TGF-β1
(PeproTech Inc.) and then incubated for 48 h.
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The HK2 cells were lysed with RIPA lysis buffer, and
then 40 μg of the total protein extract was loaded into
each well and separated by using 8 % polyacrylamide
(SDS-PAGE) protein gel electrophoresis. The proteins
were transferred onto nitrocellulose membranes. The
membranes were blocked in 1× casein (Sigma-Aldrich)
for 1 h, and the membranes were incubated with the fol-
lowing primary antibodies at 4 °C overnight:
i. Rabbit monoclonal anti-E-cadherin (1:800 dilution;
Biogot Biotechnology Co. Ltd., Nanjing, China)
ii. Rabbit monoclonal anti-alpha-smooth muscle actin
(anti-α-SMA) (1:500 dilution; Abcam, Cambridge,
MA, USA)
iii. Anti-β-actin (1:5,000 dilution; Beyotime Institute of
Biotechnology).
After excess primary antibodies were washed off, the
membranes were incubated with secondary antibodies
(Beyotime Institute of Biotechnology) diluted in 1:1000
for 2 h at room temperature. The target band was de-
tected chemiluminescently by using an enhanced chemi-
luminescence (ECL) Western Blotting kit (Applygen
Technologies Inc., Beijing, China). While β-actin was
used as internal control, the relative expression levels of
E-cadherin and α-SMA were calculated in each experi-
mental group.
Immunofluorescence
HK2 cell suspensions were seeded onto autoclaved glass
coverslips placed in six-well plates (105 cells per well).
After overnight incubation at 37 °C in 5 % CO2, cells
had adhered to the coverslips. After synchronization and
transfection based on previous methods, 10 % FBS
DMEM/F12 medium (Corning) with or without 8 ng/ml
TGF-β1 (PeproTech Inc.) was used, and the cells were
further incubated for 48 h. After fixing in 4 % parafor-
maldehyde (Beyotime Institute of Biotechnology) at
room temperature for 15 min, the cells were perme-
abilized in 0.2 % Triton X-100 (Sigma-Aldrich) for 5 min
and then blocked in 1× casein (Sigma-Aldrich) at room
temperature for 30 min. Rabbit monoclonal anti-E-
cadherin (1:100, Biogot Biotechnology Co. Ltd.) and
anti-α-SMA (1:50; Abcam) primary antibodies were di-
luted and added to the coverslips and then incubated
overnight at 4 °C. After washing with PBS, fluorescent
anti-rabbit conjugated with CY3 or FITC secondary anti-
bodies (1:400, Jackson ImmunoResearch Laboratories,
Bar Harbor, ME, USA) were added and incubated for 2
h at room temperature. After washing with PBS, the
coverslips were removed from the six-well plates and
placed on a glass slide, and mounting medium contain-
ing 4ʹ,6-diamidino-2-phenylindole (DAPI) (ZSGB-BIO,Beijing, China) was added. Random fields were chosen
under a fluorescence microscope (Olympus America Inc.,
Center Valley, PA, USA), and the expressions of E-
cadherin and α-SMA in HK2 cells were observed.
Statistical analysis
Results were expressed as the mean ± standard deviation
by using SPSS 17.0 software (IBM Corporation, Armonk,
NY, USA). Differences between experimental groups
were analyzed by using one-way analysis of variance.
P values of less than 0.05 were considered statistically
significant.
Results
Identification and senescence staining of BM-MSCs
Figure S1 in Additional file 1 shows that fewer BM-MSCs
were extracted from an equal amount of bone marrow in
older, 24-month-old rats compared with younger, 3-
month-old rats. Moreover, under the same incubation
conditions, we observed fewer adherent BM-MSCs in the
older group than in the younger rats. In addition, the
growth rate of BM-MSCs derived from young rats was sig-
nificantly faster than those derived from older rats. With
each additional passage of primary BM-MSCs derived
from older rats, we observed slower and irregular cell
growth, with wider intercellular spacing in BM-MSCs
(Additional file 1). By using SA-β-Gal staining that detects
senescent cells, we observed a higher positive staining rate
in BM-MSCs from older rats than in BM-MSCs from
younger rats (Additional file 2). According to the flow cy-
tometry data, the expression of BM-MSC surface markers,
including CD44, CD105, and CD146, was positive in both
young and older rats, whereas the expression of CD45 was
negative in both groups (Fig. 1a). Adhesion molecules,
including CD44, CD29, and α4-integrin, which are
expressed on the plasma membrane of BM-MSCs, were
detected on the surface of BM-MSC-MVs from both
young and elder rats (Fig. 1b). BM-MSCs from both young
and elder rats had the capacity to differentiate into adipo-
cytes and osteoblasts (Fig. 1c).
Aged BM-MSCs show decreased proliferation and
migration
BM-MSCs of older rats showed significantly slower growth
rate in vitro than that of younger rats (Additional file 3a).
In the transwell migration assay, compared with BM-
MSCs derived from younger rats, the migration capacity of
BM-MSCs from older rats also remarkably decreased, and
this was likely due to aging (Additional file 3b).
Change in miRNA expression profiles in BM-MSC-MVs
caused by aging
Compared with the younger group, 117 miRNAs from
BM-MSC-MVs derived from older rats were differentially
Fig. 1 Characterization of young and old MSCs as well as young and old MVs. a BM-MSCs from young and old Fisher344 rats were cultured to
passage 3 and labeled with a FITC-coupled antibodies against CD44 and CD146 and a PE/Cy7-coupled antibody against CD45 and CD105 or
immunoglobulin isotype control IgGs and analyzed by using FACS. b MVs from young and old MSCs were collected and labeled with FITC-coupled
antibodies against CD44, a4-integrin, and PE/Cy7-coupled antibody against CD29 or immunoglobulin isotype control IgGs and analyzed by using FACS.
c Representative photomicrographs show lipid inclusions with Oil Red O (left) and mineralization with alizarin red (right) in MSCs from young (top) and
old rats (bottom). FACS fluorescence-activated cell sorting, FITC fluorescein isothiocyanate, MSC mesenchymal stem cell, MV microvesicle,
PE phycoerythrin
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changes (P < 0.05): the expression levels of 14 miRNAs
were upregulated and 5 were downregulated (Fig. 2a, b).
For significantly downregulated miRNAs on the micro-
array, the expression levels in MVs were verified by RT-
PCR, and the results from both assays were in agreement.
miR-344a, miR-133b-3p, miR-294, miR-423-3p, and miR-
872-3p in BM-MSC-MVs from aged rats were downregu-
lated, and the expression of miR-294 and miR-872-3p
showed a significant decline (P < 0.05) (Fig. 2c).
Expression of miRNAs in blood
Compared with younger rats, the serum levels of miR-
344a, miR-133b-3p, miR-294, and miR-872-3p in aged
rats decreased, and those of miR-133b-3p, miR-294, and
miR-872-3p showed a significant decrease (P < 0.05)
(Fig. 2d).
Inhibition of TGF-β1-mediated EMT by BM-MSC-MV is
weakened in older rats
BM-MSC-MVs derived from younger rats showed sig-
nificant inhibitory effects on TGF-β1-mediated EMT in
HK2 cells. The addition of BM-MSC-MVs from youngerrats to TGF-β1 resulted in the stimulation of HK2 cells
to reverse the downregulated E-cadherin expression and
upregulated α-SMA expression (P < 0.05 for both). On
the other hand, BM-MSC-MVs derived from older rats
did not show such effects (Fig. 3a, b). These observations
of EMT marker expression in HK2 cells subjected to
various treatments were further confirmed by immuno-
fluorescence staining (Figs. 4a–d and 5a–d).
Effects of miRNA downregulated in elder rat BM-MSC-MVs
on TGF-β1-mediated EMT
HK2 cells were initially transfected with miR-344a, miR-
294, miR-872 -3p, miR-133b-3p, and miRNA mimic
control and then incubated in a medium containing 8
ng/ml TGF-β1 for 48 h. Compared with non-transfected
HK2 cells, the expression level of α-SMA significantly
decreased in HK2 cells transfected with miR-344a, miR-
294, and miR-133b-3p (P < 0.05), and the expression
level of E-cadherin significantly increased in HK2 cells
transfected with miR-294 and miR-133b-3p (P < 0.05).
Meanwhile, HK2 cells transfected with miR-872-3p ex-
hibited no significant changes (Fig. 3c, d). We also vali-
dated these results by immunofluorescence staining,
Fig. 2 Age-dependent changes in miRNA profiles of young and old MVs. a Expression of miRNAs in young and old MVs and mapping of
hierarchic clustering of miRNAs and heatmap display of miRNA profiles. b Significant fold changes in miRNAs (fold change > 1.5) in old MVs
versus young MVs. Upregulated miRNAs were marked in red, and downregulated miRNAs are indicated in green. c RT-PCR analysis was used
to validate the downregulated miRNAs in young and old MVs. d RT-PCR analysis was employed to validate the downregulated miRNAs in
serum from young and old rats (*P < 0.05; **P < 0.01; n = 5). miRNA microRNA, MV microvesicle, RT-PCR reverse transcription-polymerase
chain reaction
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tion displayed high expression of E-cadherin and low ex-
pression of α-SMA. After TGF-β1 stimulation, HK2 cells
presented lower expression of E-cadherin and higherexpression of α-SMA. Moreover, miR-344a, miR-294,
and miR-133b-3p weakened the upregulation of α-SMA
and inhibited the downregulation of E-cadherin in HK2
cells induced by TGF-β1 (Figs. 4e-i and 5e-i).
Fig. 3 Effect of MVs and miRNAs on the inhibitory effect of TGF-β1 on the EMT in HK2 cells. a, c Western blot analysis of E-cadherin and α-SMA
expression in HK2 cells under TGF-β1 stimulation co-cultured with Y-MV /O-MV or pre-transfection with miR-872, miR-344, miR-294, miR-133b -3p,
and miR-control mimic. β-actin was used as internal control. b, d Quantification of E-cadherin and α-SMA protein levels in HK2 cells from each
experimental group. **P < 0.05; n =3. α-SMA alpha-smooth muscle actin, EMT epithelial-mesenchymal transition, MV microvesicle, TGF-β1
transforming growth factor-beta 1
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Renal interstitial fibrosis is a characteristic pathology of
aging kidneys and the basis of CKD progression. EMT of
renal tubules is the leading cause of renal interstitial fi-
brosis. Several studies have shown that TGF-β1 en-
hances EMT through a variety of mechanisms [21–23].
In addition, various studies have demonstrated that BM-
MSCs participate in renal tissue repair. Morigi et al. [24]
showed that BM-MSCs can improve kidney functions,
and BM-MSCs are the primary cell population involved
in renal tubular and functional repair. Other recent in-
vestigations have also shown that BM-MSCs can reduce
renal damage through paracrine activity [25–27].
MVs are small circular diaphragms (diameter of 100
nm to 1 μm) shed from the cell surface or released from
cellular compartments. MVs contain proteins, enzymes,
mRNA, and miRNA and may participate in tissue dam-
age repair through paracrine activity [15, 17, 27].Camussi et al. [15] revealed that both BM-MSCs and
BM-MSC-MVs promote morphological restoration and
renal function maintenance in animals with renal
ischemia-reperfusion or unilateral nephrectomy. MVs se-
creted by BM-MSCs can enter the damaged kidney cells
and play a role in kidney repair. Cantaluppi et al. [28]
also observed that MVs in rats possessed a repair func-
tion for renal ischemia-reperfusion injury. However, pre-
treatment with an efficient miRNA blocker resulted in a
reduction in repair function, suggesting that MVs can
transfer miRNAs to repair damaged kidneys.
In eukaryotes, miRNAs play an extremely important
role in organ development and maturation as well as the
pathogenesis and progression of disease [29]. Previous
studies have shown that in fibrotic renal tissues the ex-
pressions of both miR-200 family and E-cadherin are
significantly downregulated and that exogenous miR-200
could reduce renal fibrosis [30, 31]. Pre-transfection of
Fig. 4 Immunocytochemical analysis of E-cadherin staining: Representative images of anti-E-cadherin staining in HK2 cells from each experimental
group. The green staining shows the expression of E-cadherin in normal HK2 cells that were (a) treated with TGF-β1 (b) or co-cultured with Y-MV
(c) or Old-MV (d). It also indicated the expression of E-cadherin in HK2 cells treated with TGF-β1 but pre-transfected with miR-872, miR-344,
miR-294, miR-133b-3p, and miR-control mimic (e-i). TGF-β1 transforming growth factor-beta 1
Fig. 5 Immunocytochemical staining of α-SMA in HK2 cells from each experimental group. The red staining shows the expression of α-SMA in
normal HK2 cells that were (a) treated with TGF-β1 (b) or co-cultured with Y-MV (c) or Old-MV (d). It also indicated the expression of α-SMA in
HK2 cells treated with TGF-β1 but pre-transfected with miR-872, miR-344, miR-294, miR-133b-3p, and miR-control mimic (e–i). α-SMA alpha-smooth
muscle actin, TGF-β1 transforming growth factor-beta 1
Wang et al. Stem Cell Research & Therapy  (2015) 6:185 Page 8 of 11
Wang et al. Stem Cell Research & Therapy  (2015) 6:185 Page 9 of 11the miR-200 family can reverse TGF-β1-mediated EMT
in tubular epithelial cells [30, 32, 33]. Through the regu-
lation of Tgfbr2 and Gsk3-beta, miR-294/302 can inhibit
TGF-beta and GSK3 pathways. On the other hand, miR-
294/302 can indirectly inhibit Tgfbr2 as well as EMT of
embryonic stem cells [34]. Liu et al. discovered that, as a
downstream gene of fibrotic TGF-β/Smad3 pathway,
miR-133 can negatively regulate TGF-β/Smad3 [35].
Along with physiological aging, BM-MSCs also age, and
the cellular molecules these secrete significantly decrease
or even disrupt secretion. Expression profiles of miRNAs
can also significantly change with age, and its functions
against diseases can decrease or become ineffective [36, 37].
In the present study, we found that the number of
BM-MSCs derived from 24-month-old rats was signifi-
cantly lower, displayed a senescent phenotype, and had a
markedly slower in vitro proliferation rate compared
with that observed in 3-month-old rats. Furthermore,
these aged BM-MSCs showed irregular growth with in-
creased cellular spacing, and their migration ability was
significantly weaker. We also observed significant differ-
ences in miRNA expression of BM-MSC-MVs between
younger and older rats. Compared with younger rats,
five miRNAs in BM-MSC-MVs—miR-344a, miR-133b-
3p, miR-294, miR-423-3p, and miR-872-3p—were sig-
nificantly reduced in older rats. Additionally, compared
with MVs from younger rats, the inhibitory effects of
MVs from older rats on TGF-β1-induced EMTs were
significantly reduced. We also observed that miR-133b-
3p and miR-294, which were downregulated in older
rats, imparted significant inhibitory effects on TGF-β1-
induced EMT. Our data therefore suggested that the
downregulation of miR-133b-3p and miR-294 in older
rats may be an important cause of suppression of TGF-
β1-induced EMT in aged rats.
In recent years, studies have shown that changes in
body environment affect aging of organs. Through the
establishment of Siamese animal models such as young
and older rats, we observed that learning and
memorization were enhanced in older rats but that these
were weakened in younger rats. With injection of serum
from older rats, younger rats presented brain aging phe-
notypes. Conversely, injection of serum from younger
rats resulted in the alleviation of the brain aging pheno-
type in older rats [38]. In the young-elderly rat model,
cardiac hypertrophy of aged hearts was significantly less
than that of the elder-elder rat model, and cardiac func-
tion significantly improved [39]. In addition, in the
young-elderly rat model, aged muscles, liver, neural
stem/progenitor cells, and ovarian follicles were acti-
vated, and the regeneration capacity of tissues and or-
gans was enhanced [40–42]. The miRNAs contained in
BM-MSC-MVs can be released into blood circulation,
where they are converted into circulating miRNAs thatpossess the ability to change the internal environment,
and ultimately impart systemic effects. Our current ex-
perimental results showed that miRNAs that were
downregulated in MVs from older rats also exhibited a
comparatively low level in serum, suggesting that by se-
creting MVs and changing miRNA expression, BM-
MSCs changed the body environment during the aging
process. In older rats, the level of secreted miR-133b-3p
and miR-294 decreased. Their levels in serum were also
low and this may be an important factor in causing renal
EMT and renal aging.
In the present study, we confirmed that, in older rats,
the inhibitory effects of BM-MSC-MVs on TGF-β1-
induced EMT had weakened, and this might be related
to the decrease in the levels of miR-133b-3p and miR-
294. However, the target genes, regulatory mechanisms,
and signaling pathways of miR-133b-3p and miR-294
currently remain unclear and should be investigated in
future studies.
Conclusions
The present study observed that the inhibitory effect of
BM-MSC-MVs on TGF-β1-mediated HK2 cell EMT was
weaker in older rats than in younger rats. Moreover,
miR-133b-3p and miR-294, which were downregulated
in BM-MSC-MVs and serum of older rats, could re-
markably inhibit TGF-β1-mediated EMT in HK2 cells.
These findings suggest that the downregulated miR-
133b-3p and miR-294 in older rats play important roles
in causing renal EMT and renal aging.
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